ArticleThe journal for nurse practitioners : JNP2021
COVID-19 Management in Pediatrics.
Article in The journal for nurse practitioners : JNP, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Influence of COVID-19 on pediatric immunocompromised children: mechanism and implications for pathogenesis.Virusdisease · 2025Review
- The use of monoclonal antibody therapy in pediatric patients with COVID-19: a retrospective case series.International journal of emergency medicine · 2022Article
- The COVID-19 pandemic in children and young people during 2020-2021: Learning about clinical presentation, patterns of spread, viral load, diagnosis and treatment.Journal of global healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus disease 2019 (COVID-19) is a deadly global pandemic, with scientific efforts improving our understanding of this novel coronavirus. No proven disease-specific therapies exist, although 2 vaccines have been recently approved by the United States Food and Drug Administration under emergency use authorization, and several others are in development or phase III clinical trial testing. COVID-19 presents in greater severity in the medically fragile, obese, elderly, and socially disadvantaged, and children in general are less affected. All children are at risk, but those with comorbidities and neonates are more susceptible. The multisystem inflammatory syndrome is a severe version which can present in any child with a recent COVID-19 infection. The face of the pandemic has been changing in the last few months, with recent increasing cases, virus mutations, and onset of vaccination. This article provides COVID-19 management for children and adolescents and implications for nursing and advanced practice providers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.